External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home IMS 2026
Roche and Genentech at

IMS 2026

September 23 - September 26
Glasgow, Scotland / Virtual (Hybrid)
ims26.myexpoonline.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
12:00 PM
Duration 240mins Glasgow, Scotland
CEVOLUTION: A randomized phase III trial comparing cevostamab plus pomalidomide and dexamethasone (pom-dex) versus standard of care (SOC) in relapsed/refractory multiple myeloma (RRMM)
Rakesh Popat, Adam Cohen, Amrita Krishnan, Divya Samineni, Elena Zamagni, Hira S. Mian, Joshua Richter, Kerstin Trunzer, Tulika Tyagi, Leanne Richardson, Paresh Sewpaul,, Sammy Chebon, Tina Nielsen, Binod Dhakal
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:06 PM
Duration 12mins Glasgow, Scotland
Cevostamab plus pomalidomide (pom) and dexamethasone (dex) induces durable remissions in BCMA-naïve patients with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm B extended follow-up data
Andrew Spencer, Hira S Mian, Kihyun Kim, Laura Paris, Rakesh Popat, Simon J Harrison, Anna Caroline Hasselbalch, Noa Lavi, Tomas Jelinek, Monika Szarejko, Sebastian Grosicki, Irwindeep Sandhu, Vanessa Grassi, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Ameet Mishra, Suzanne Trudel
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:36 AM
Duration 12mins Glasgow, Scotland
A fixed-duration, modified cevostamab dosing regimen induces durable remissions that continue after completion in BCMA-naïve pts with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm A results
Ravi Vij, Amrita Krishnan, Henning Schade, Simon Harrison, Suzanne Trudel, Ameet Mishra, Vanessa Grassi, Tulika Tyagi, Divya Samineni, Leanne Richardson
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:30 AM
Duration 50mins Glasgow, Scotland
Cevostamab: A FcRH5xCD3 bispecific antibody for the treatment of multiple myeloma
Paresh Sewpaul
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.